Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Cipla
UBS
Chubb
Fuji
Dow
Healthtrust
Johnson and Johnson
Cantor Fitzgerald

Generated: December 13, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CANDESARTAN CILEXETIL

« Back to Dashboard

Clinical Trials for Candesartan Cilexetil

Trial ID Title Status Sponsor Phase Summary
NCT00108706 Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST) Unknown status Takeda Phase 4 The aim of this study is to determine whether it is safe and effective to give the Angiotensin Receptor Blocker (ARB) Candesartan within the first 72 hours following acute stroke.
NCT00108706 Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST) Unknown status City Hospitals Sunderland NHS Foundation Trust Phase 4 The aim of this study is to determine whether it is safe and effective to give the Angiotensin Receptor Blocker (ARB) Candesartan within the first 72 hours following acute stroke.
NCT00125463 Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients Unknown status The Japanese Society of Hypertension Phase 3 The purpose of this study is to compare an angiotensin II receptor antagonist (candesartan cilexetil– Blopress®) and a calcium channel blocker (amlodipine besilate– Norvasc®/Amlodin®) in terms of the incidence of cardiovascular events among high-risk hypertensive patients.
NCT00139386 Candesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) Trial Completed Japan Heart Foundation Phase 4 Candesartan is effective in preventing cardiovascular events in patients without restenosis after coronary angioplasty. Therefore, the investigators hypothesized that candesartan after drug-eluting stent (DES) implantation was also effective in preventing cardiovascular events. The purpose of this study is to investigate whether an angiotensin II receptor blocker, candesartan, is effective in reducing the incidence of cardiovascular events after drug-eluting stent implantation.
NCT00139386 Candesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) Trial Completed The 4C trial bureau Phase 4 Candesartan is effective in preventing cardiovascular events in patients without restenosis after coronary angioplasty. Therefore, the investigators hypothesized that candesartan after drug-eluting stent (DES) implantation was also effective in preventing cardiovascular events. The purpose of this study is to investigate whether an angiotensin II receptor blocker, candesartan, is effective in reducing the incidence of cardiovascular events after drug-eluting stent implantation.
NCT00139386 Candesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) Trial Completed Kumamoto University Phase 4 Candesartan is effective in preventing cardiovascular events in patients without restenosis after coronary angioplasty. Therefore, the investigators hypothesized that candesartan after drug-eluting stent (DES) implantation was also effective in preventing cardiovascular events. The purpose of this study is to investigate whether an angiotensin II receptor blocker, candesartan, is effective in reducing the incidence of cardiovascular events after drug-eluting stent implantation.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Candesartan Cilexetil

Condition Name

Condition Name for Candesartan Cilexetil
Intervention Trials
Hypertension 25
Essential Hypertension 5
Healthy 3
Cerebrovascular Accident 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Candesartan Cilexetil
Intervention Trials
Hypertension 26
Heart Failure 4
Retinal Diseases 3
Diabetic Retinopathy 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Candesartan Cilexetil

Trials by Country

Trials by Country for Candesartan Cilexetil
Location Trials
United States 100
Japan 30
Korea, Republic of 19
United Kingdom 13
Canada 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Candesartan Cilexetil
Location Trials
California 6
Ohio 5
North Carolina 5
Florida 5
Texas 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Candesartan Cilexetil

Clinical Trial Phase

Clinical Trial Phase for Candesartan Cilexetil
Clinical Trial Phase Trials
Phase 4 9
Phase 3 23
Phase 2 5
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Candesartan Cilexetil
Clinical Trial Phase Trials
Completed 37
Unknown status 9
Not yet recruiting 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Candesartan Cilexetil

Sponsor Name

Sponsor Name for Candesartan Cilexetil
Sponsor Trials
AstraZeneca 19
Takeda 13
CJ HealthCare Corporation 6
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Candesartan Cilexetil
Sponsor Trials
Industry 52
Other 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Argus Health
Cipla
Farmers Insurance
Baxter
Boehringer Ingelheim
Julphar
Colorcon
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.